Bicara Therapeutics develops ficerafusp alfa, an investigational antibody therapy for solid tumors such as head and neck cancers. BCAX reports earnings on Mon, Nov 9, 2026. Analyst consensus is Buy, based on the latest ratings from 7 firms (4 buy, 2 hold, 1 sell). In the past 30 days there were 2 dark pool prints.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 30 | Goldman Sachs | Downgrade | Sell | |
| Oct 29 | Wedbush | Target lowered | Buy | |
| Aug 19 | BMO Capital | Initiated | Buy | |
| Aug 12 | Goldman Sachs | Maintained | Hold | |
| Aug 12 | Wedbush | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in BCAX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BCAX is in one of them and how their past BCAX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BCAX in an article yet. Here's the latest on the wider market.
About Bicara Therapeutics
Bicara Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that is developing treatments for solid tumors. Its main candidate, ficerafusp alfa, is an investigational antibody that pairs an antibody targeting the EGFR protein on tumor cells with a molecule that blocks TGF-β, a signaling protein that helps tumors resist treatment. The candidate is being tested mainly in head and neck squamous cell carcinoma, and the company does not yet sell a product. Its intended patients are people with solid tumors, starting with head and neck cancers.
- Headquarters
- Boston, MA